The KDM5B Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the histone demethylase KDM5B. This loss-of-function model enables pooled studies of KDM5B-dependent processes without clonal selection bias, preserving genetic heterogeneity relevant to cancer cell populations.
The parental PaTu 8988t cell line is a human pancreatic ductal adenocarcinoma (PDAC) model derived from a liver metastasis, thus representing metastatic disease. It carries KRAS G12V and TP53 mutations, common in PDAC, making it highly suitable for studies of tumor progression, metastasis, and therapeutic resistance.
KDM5B functions as a histone H3K4 demethylase, removing activating methyl marks to repress transcription of tumor suppressors including CDKN2A (p16INK4a), CDKN1A (p21Cip1), and CDH1 (E-cadherin). It interacts with transcriptional repressor complexes containing HDAC1, HDAC2, LSD1, REST, and PRC2 components. Upstream regulators such as HIF1??, E2F1, MYC, and TP53 control KDM5B expression, while downstream it promotes cell cycle progression by repressing the RB1/E2F1 pathway and drives EMT via activation of VIM and SNAI1.
In the KRAS/TP53-mutant PaTu 8988t background, KDM5B knockout is expected to derepress its target genes, leading to reduced proliferation and possibly senescence or apoptosis. This model thus enables dissection of KDM5B??s role in maintaining the aggressive phenotype of metastatic pancreatic cancer, including its contributions to hypoxia signaling, DNA damage response, and Wnt/??-catenin pathway activation.
Researchers can apply these cells in functional assays such as proliferation, colony formation, migration, and invasion analyses to characterize KDM5B??s impact on malignancy. They support drug target validation, inhibitor screening, and synthetic lethality approaches. Epigenetic changes can be assessed by ChIP-qPCR for H3K4me3 and western blot for target proteins, while transcriptomic responses are amenable to RNA-seq. For details, contact Ascent Research.
